A Multicenter, Randomized, Open-label Trial to Compare Bone Mineral Density and Fat Free Mass in Men GivenReceiving Either Goserelin Acetate (ZOLADEXTM) 10.8- mg Depot or Bicalutamide (CASODEXTM) 150 mg for Treatment of Prostate Cancer.

Study identifier:7054US/0004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Randomized, Open-label Trial to Compare Bone Mineral Density and Fat Free Mass in Men GivenReceiving Either Goserelin Acetate (ZOLADEXTM) 10.8- mg Depot or Bicalutamide (CASODEXTM) 150 mg for Treatment of Prostate Cancer.

Medical condition

prostate cancer

Phase

Phase 4

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Mar 1998
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria